- Home
- CATO vs BNTC Comparison
CATO vs BNTC Comparison
Compare CATO & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CATO | BNTC |
|---|---|---|
| Founded | 1946 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.8M | 405.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CATO | BNTC |
|---|---|---|
| Price | $3.13 | $13.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $28.25 |
| AVG Volume (30 Days) | 46.7K | ★ 253.4K |
| Earning Date | 11-20-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $660,062,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.19 | $9.70 |
| 52 Week High | $4.92 | $17.15 |
Technical Indicators
Market Signals| Indicator | CATO | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 41.06 | 52.41 |
| Support Level | $3.00 | $10.99 |
| Resistance Level | $3.52 | $13.36 |
| Average True Range (ATR) | 0.23 | 0.97 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 26.32 | 83.20 |
Price Performance
Historical ComparisonAbout CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.